𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment

✍ Scribed by Stefanie Naundorf; Susanne Preithner; Petra Mayer; Sandra Lippold; Andreas Wolf; Frank Hanakam; Iduna Fichtner; Peter Kufer; Tobias Raum; Gert Riethmüller; Patrick A. Baeuerle; Torsten Dreier

Publisher
John Wiley and Sons
Year
2002
Tongue
French
Weight
326 KB
Volume
100
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In our study, a novel, fully human, recombinant monoclonal antibody of the IgG1 isotype, called MT201, was characterized for its binding properties, complement‐dependent (CDC) and antibody‐dependent cellular cytotoxicity (ADCC), as well as for its in vivo antitumor activity in a nude mouse model. MT201 was found to bind its target, the epithelial cell adhesion molecule (Ep‐CAM; also called 17‐1A antigen, KSA, EGP‐2, GA733‐2), with low affinity in a range similar to that of the clinically validated, murine monoclonal IgG2a antibody edrecolomab (Panorex®). MT201 exhibited Ep‐CAM‐specific CDC with a potency similar to that of edrecolomab. However, the efficacy of ADCC of MT201, as mediated by human immune effector cells, was by 2 orders of magnitude higher than that of edrecolomab. Addition of human serum reduced the ADCC of MT201 while it essentially abolished ADCC of edrecolomab within the concentration range tested. In a nude mouse xenograft model, growth of tumors derived from the human colon carcinoma line HT‐29 was significantly and comparably suppressed by MT201 and edrecolomab. The fully human nature and the improved ADCC of MT201 with human effector cells will make MT201 a promising candidate for the clinical development of a novel pan‐carcinoma antibody that is superior to edrecolomab. © 2002 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

CNTO 95, a fully human monoclonal antibo
CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo
✍ Mohit Trikha; Zhao Zhou; Jeffrey A. Nemeth; Qiming Chen; Celia Sharp; Eva Emmell 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 294 KB

## Abstract Integrins of the αv family, such as αvβ3 and αvβ5, are implicated in tumor‐induced angiogenesis; but their role in tumor growth has not been fully explored. CNTO 95 is a fully human antibody that recognizes the αv family of integrins and is likely to be less immunogenic in humans compar

Efficient neutralizing activity of cockt
Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis a virus infection in vitro and in vivo
✍ Jingyuan Cao; Shufang Meng; Chuan Li; Yan Ji; Qingling Meng; Quanfu Zhang; Feng 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

## Abstract Hepatitis A virus (HAV) is the major pathogen responsible for acute infectious hepatitis A, a disease that is prevalent worldwide. Although HAV immunization effectively prevents infection, primary immunizations must be administered at least 2 weeks prior to HAV exposure. In contrast, pa

In vivo suppression of T-dependent antib
In vivo suppression of T-dependent antibody responses by treatment with a monoclonal anti-L3T4 antibody
✍ Pierre G. Coulie; Jean-Paul Coutelier; Catherine Uyttenhove; Paul Lambotte; Jacq 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

Minute amounts of the anti-L3T4 antibody designated GK1.5 were found to deeply suppress in vivo antibody responses to T-dependent antigens. Primary responses to sheep erythrocytes were completely inhibited even when GK1.5 was administered up to 6 days before or 4 days after the antigen. Secondary re